Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

Genetic analysis of metastatic castration resistant prostate cancer patients treated with Lu-177 PSMA radioligand therapy. Received radium-223 prior 2/19 (10.5%) 0/13 (0.0%) 2/6 (33.3%) 2/3 (66.6%) ...

The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape ...

Real-world clinical practice gaps in timely homologous recombination repair gene mutation (HRRm) testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...

The addition of neoadjuvant Lutetium-177 (Lu-177) therapy to metastasis-directed stereotactic body radiation therapy (SBRT) more than doubled progression-free survival (PFS) in men with ...